Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  ALK-Abello A/S    ALK B   DK0060027142

ALK-ABELLO A/S (ALK B)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
10/16/2017 10/17/2017 10/18/2017 10/19/2017 10/20/2017 Date
1033(c) 1025(c) 1018(c) 1002(c) 1008(c) Last
8 450 6 890 16 495 7 814 6 013 Volume
+1.47% -0.77% -0.68% -1.57% +0.60% Change
More quotes
Financials ( DKK)
Sales 2017 2 973 M
EBIT 2017 89,9 M
Net income 2017 12,7 M
Debt 2017 646 M
Yield 2017 0,45%
Sales 2018 3 206 M
EBIT 2018 260 M
Net income 2018 134 M
Debt 2018 647 M
Yield 2018 0,55%
P/E ratio 2017 1 202,43
P/E ratio 2018 83,62
EV / Sales2017 3,34x
EV / Sales2018 3,10x
Capitalization 9 281 M
More Financials
Company
ALK-Abello A/S engages in the production and development of pharmaceutical products to prevent and treat allergies.It also manufactures tablet-based allergy vaccines for pollen, house dust mites, animals and insect stings.Its treatment comprises of allergy vaccines, emergency treatment and allergy... 
Sector
Pharmaceuticals
Calendar
11/10Earnings Release
More about the company
Surperformance© ratings of ALK-Abello A/S
Trading Rating : Investor Rating :
More Ratings
Latest news on ALK-ABELLO A/S
10/12 ALK ABELLO A/S : Notification of ownership in ALK
09/27 ALK ABELLO A/S : partner, Torii, gains approval for Japanese cedar SLIT-tablet i..
09/21 ALK ABELLO A/S : acts on French injunction by accelerating investments in its qu..
09/14 ALK ABELLO A/S : Successful Phase III trial for ALK's tree allergy SLIT-tablet
08/22 ALK ABELLO A/S : Hunting stingers for science
08/22 ALK ABELLO A/S : Turning venom into medicine
08/22 ALK ABELLO A/S : Virginia bee buster helps turn venom into treatment
08/22 ALK ABELLO A/S : Hunting stingers for science Virginia bee buster helps turn ven..
08/21 ALK ABELLO A/S : Virginia bee buster helps turn venom into treatment
08/11ALK-ABELLO A/S : half-yearly earnings release
More news
Sector news : Pharmaceuticals - NEC
10/21 JOHNSON & JOHNSON : California judge tosses $417 million talc cancer verdict aga..
10/20DJMERCK AND : to Lay Off About 1,800 U.S. Sales Reps in Cost-Cutting Move
10/20 MERCK AND : to cut 1,800 U.S. sales jobs, add 960 in chronic care
10/20DJABBOTT LABORATORIES : Hacking Is a Risk for Pacemakers. So Is the Fix
10/19DJCELGENE : Halts Crohn's Disease Drug Trials
More sector news : Pharmaceuticals - NEC
Latest Tweets
10/12Global Allergy Immunotherapy Market 2017-2021 Featuring ALK-Abello, Allergy T.. 
10/12Global Allergy Immunotherapy Market 2017-2021 Featuring ALK-Abello, Allergy T.. 
09/27ALK Abello A/S : partner, Torii, gains approval for Japanese cedar SLIT-table.. 
09/14ALK Abello A/S : Successful Phase III trial for ALK's tree allergy SLIT-table.. 
08/16ALK-ABELLO AS B SHS 2017 Q2 - Results - Earnings Call Slides  
More tweets
Qtime:19
News from SeekingAlpha
08/21 ALK accelerates commercial launch of dust mite tablet in North America to Q4;..
08/16 ALK-ABELLO AS B SHS 2017 Q2 - Results - Earnings Call Slides
07/19 FDA's Flashing Green Light Boosts Novel Drug Approvals
07/07 ALK-Abello reports positive child asthma results from Grazax trial
Chart ALK-ABELLO A/S
Duration : Period :
ALK-Abello A/S Technical Analysis Chart | ALK B | DK0060027142 | 4-Traders
Technical analysis trends ALK-ABELLO A/S
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 7
Average target price 1 049  DKK
Spread / Average Target 4,0%
EPS Revisions
Managers
NameTitle
Carsten Hellmann President & Chief Executive Officer
Steen Riisgaard Chairman
Flemming Pedersen Chief Financial Officer & Executive Vice President
Henrik Hugo Jacobi Executive Vice President-Research & Development
Anders Gersel Pedersen Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ALK-ABELLO A/S10.65%1 470
JOHNSON & JOHNSON23.29%382 202
NOVARTIS13.50%226 404
PFIZER11.58%216 886
ROCHE HOLDING LTD.5.55%207 116
MERCK AND COMPANY7.88%174 223